PFE Pfizer, a darling of the Covid pandemic era is currently down from 56$
Pfizer emerged as a significant beneficiary during the Covid-19 era, witnessing a surge in its stock price. However, as the Covid-19 concern recedes, its share price has also returned most of its gains. Nevertheless, Pfizer's success isn't solely dependent on a single event, as it possesses a diverse portfolio of drugs that contribute to a more varied revenue stream. Although the Covid-19 vaccines brought substantial profits to Pfizer, its resilience lies in its broader pharmaceutical offerings. Morningstar has provided a fair valuation of $48, indicating a potential upside of 46%.
Conservatives target are at $36 - $42 still a massive upside opportunity
Pfizer emerged as a significant beneficiary during the Covid-19 era, witnessing a surge in its stock price. However, as the Covid-19 concern recedes, its share price has also returned most of its gains. Nevertheless, Pfizer's success isn't solely dependent on a single event, as it possesses a diverse portfolio of drugs that contribute to a more varied revenue stream. Although the Covid-19 vaccines brought substantial profits to Pfizer, its resilience lies in its broader pharmaceutical offerings. Morningstar has provided a fair valuation of $48, indicating a potential upside of 46%.
Conservatives target are at $36 - $42 still a massive upside opportunity
Publicações relacionadas
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.
Publicações relacionadas
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.